Updates Center

• 
  AtaGenix March 2026 Research Highlights: Collaborative Breakthroughs Published in Top Journals

  In March 2026, AtaGenix supported multiple groundbreaking studies that were successfully published in high-impact journals including Cancer Research, Nature Communications, Cell Reports Medicine, and Nature Sensors. These collaborative achievements span key areas such as colorectal cancer immune evasion, dendritic cell immunosuppression, centrosome maturation, HE4-mediated PD-L1 regulation, and ultrasensitive nanobody-based FET biosensors for endometrial cancer detection. By providing highly specific custom antibodies and nanobodies, AtaGenix played a crucial role in validating novel molecular mechanisms and advancing innovative diagnostic and therapeutic strategies in life sciences.
• 
  AtaGenix March 2026 Publications: Breakthroughs in Cancer Research & Nanobody Technology

  In March 2026, AtaGenix supported multiple groundbreaking studies through its advanced custom antibody and nanobody services. Collaborative research成果 were published in high-impact journals including Cancer Research, Nature Communications, Cell Reports Medicine, and Nature Sensors. The studies explore key mechanisms in tumor immune evasion, dendritic cell immunosuppression, centrosome maturation, and ultrasensitive cancer biomarker detection using oriented nanobodies in FET biosensors. These achievements span colorectal cancer, lung adenocarcinoma, endometrial cancer, and regenerative biology, highlighting AtaGenix’s commitment to enabling cutting-edge life science research with reliable, high-specificity reagents.
• 
  AtaGenix-Supported Research Breakthroughs in April 2026: Published in The Plant Cell and Journal of Virology

  In April 2026, AtaGenix provided core technical support to multiple research teams, resulting in several high-impact publications in leading international journals, including The Plant Cell and Journal of Virology. The studies covered diverse frontier topics such as the molecular regulation of soybean root nodule senescence, ultrasensitive detection of SARS-CoV-2 S protein RBD, host antiviral mechanisms against porcine epidemic diarrhea virus (PEDV), and innate immune response to grass carp reovirus (GCRV). By supplying custom antibodies, recombinant proteins, and professional technical services, AtaGenix played a crucial role in enabling these discoveries. This showcases AtaGenix’s commitment to empowering global life science research through reliable one-stop solutions.